HeartFlow, Inc., a leading innovator in non-invasive artificial intelligence (AI) solutions for heart care, has launched its next-generation HeartFlow Plaque Analysis platform. This advanced tool, unveiled at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C., represents a significant leap forward in coronary artery disease (CAD) risk assessment and personalized patient care.

The new HeartFlow Plaque Analysis platform is notable for its integration with Fractional Flow Reserve Computed Tomography (FFRCT) when performed. This integration allows for a comprehensive view of coronary artery health by combining highly accurate plaque quantification with lesion-specific FFRCT values. The platform’s enhanced interactive experience includes a 3D model that details plaque volume and type, and offers cross-sectional, color-coded images of plaque along the coronary arteries.

Dr. Sarah Rinehart, M.D., F.A.C.C., F.S.C.C.T., medical director of CV imaging, nuclear, and CT in Charleston, WV, highlighted the transformative impact of this technology: “Having access to a patient’s whole coronary picture, with both quantified plaque and physiology, is a game changer as a clinician. I can reference the cross-sectional views with plaque by type when reviewing my patient’s workup and have confidence in the accuracy and actionable insights that I know I’ll get from HeartFlow Plaque Analysis. With a quantitative measurement of a patient’s plaque volume, I can more accurately assess risk and develop a personalized, targeted treatment plan.”

HeartFlow’s new Plaque Analysis tool offers significant advantages for patient care. The comprehensive view of plaque burden allows clinicians to tailor treatment plans more precisely. According to published prospective data, the technology demonstrates 95% agreement with the gold standard Intracoronary Ultrasound (IVUS) for total plaque volume measurements.

Furthermore, data indicates that two out of three patients had their medical management adjusted based on insights provided by the HeartFlow Plaque Analysis.

HeartFlow’s continued investment in advanced diagnostic technologies aligns with its commitment to enhancing patient care and diagnostic accuracy. The introduction of the HeartFlow Plaque Analysis platform marks an exciting advancement in AI-enabled cardiac technology, offering a fully integrated view of coronary artery disease. HeartFlow’s suite of non-invasive technologies, including FFRCT Analysis, RoadMap Analysis, and Plaque Analysis, underscores the company’s role as a pioneer in the field.

Chief Medical Officer Campbell Rogers, M.D., F.A.C.C., commented on the significance of this advancement: “Accurately diagnosing a patient’s risk for coronary artery disease is critical for determining the best treatment. Our new interactive plaque experience marks an exciting era in AI-enabled cardiac technology, where we are now the only company that offers a fully integrated view of a patient’s true burden of coronary artery disease. The elevated visualization of Plaque Analysis integrated with our flagship FFRCT Analysis, sets HeartFlow apart as a holistic solution for CT analysis, enabling physicians to enhance personalized treatment decisions.”

HeartFlow, Inc. continues to lead the way in AI-powered, non-invasive heart care solutions with the launch of its next-generation HeartFlow Plaque Analysis platform. By integrating advanced plaque analysis with FFRCT, HeartFlow provides a powerful tool for improving CAD diagnosis and treatment. As the company advances towards expanded Medicare coverage for its technologies, it remains at the forefront of transforming precision coronary care and enhancing patient outcomes.

Key Points:

– HeartFlow, Inc. introduces the next-generation HeartFlow Plaque Analysis platform with an interactive experience.

– The upgraded tool integrates with Fractional Flow Reserve Computed Tomography (FFRCT) for enhanced clinical decision-making.

– The new system creates detailed 3D models of plaque volume and characteristics, improving coronary artery disease risk assessment.

– The technology was showcased at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C.

– HeartFlow Plaque Analysis boasts 95% agreement with the gold standard IVUS and has improved medical management for many patients.

  AI heart care, AI heart care solutions, coronary artery disease, coronary artery disease risk assessment, FFRCT, FFRCT integration, HeartFlow, HeartFlow Plaque Analysis, medical technology, non-invasive diagnostics, Plaque Analysis, SCCT Annual Meeting, SCCT meeting 2024